Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Latest Information Update: 03 Oct 2023
At a glance
- Drugs Bevacizumab (Primary) ; Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Cyclophosphamide (Primary) ; Dalnicastobart (Primary) ; Dalnicastobart (Primary) ; Exlinkibart (Primary) ; Exlinkibart (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary) ; Pradusinstobart (Primary) ; Pradusinstobart (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 12 Sep 2023 Planned End Date changed from 31 Jul 2023 to 2 Feb 2027.
- 12 Sep 2023 Planned primary completion date changed from 31 Jul 2023 to 2 Feb 2027.
- 23 Nov 2021 Status changed from not yet recruiting to recruiting.